Home infusion and local blood draws for trial drugs after the first cycles
Once a patient has safely had the first few doses of a trial drug at the hospital, later doses could be given at home or a local clinic, with blood tests done nearby, so distance no longer decides who can join.
Protocols pre-specify a decentralised phase: after two or three supervised cycles, eligible patients receive subcutaneous or infused trial drug via home-infusion nursing or a local clinic under the site investigator's oversight, with labs at community draw stations, ePRO-based toxicity capture and telehealth visits. Pandemic-era regulatory flexibilities showed feasibility; the idea is to write it into protocols by default for drugs with predictable safety.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Trials do not represent the people who get cancer · Older, Black, Hispanic, Asian, rural, poor and multimorbid patients are under-represented, so results may not apply to them.
Pages like this
not linked directly; found by shared links- IdeaApprove cancer biosimilars on analytics and pharmacokinetics, no efficacy trials
Shares Trastuzumab, Monoclonal antibodies, Nivolumab, Pembrolizumab.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaPay trial participants for their time, not only their expenses
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
- IdeaTravel, lodging and meals reimbursed as a standard line in every trial budget
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaBiosimilar-first defaults and payment parity in every cancer day unit
Shares Trastuzumab, Monoclonal antibodies.
- IdeaCommunity health workers and trusted local organisations paid to recruit for trials
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.